Transcriptional profiles of type 2 diabetes in human skeletal muscle reveal insulin resistance, metabolic defects, apoptosis, and molecular signatures of immune activation in response to infections

Biochemical and Biophysical Research Communications

Volumn 482, Issue 2, 2017, Pages 282-288

  Wu, Chun ^a   Xu, Gang ^a   Tsai, Shang Yi A ^b   Freed, William J ^b,c   Lee, Chun Ting ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c LEBANON VALLEY COLLEGE   (United States)

Author keywords

Immune activation; Insulin resistance; Metabolic defects; Transcriptome; Type 2 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE SYNTHASE 5A; ADENOSINE TRIPHOSPHATE SYNTHASE 5H; ADENOSINE TRIPHOSPHATE SYNTHASE 5J; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; GLUCOSE TRANSPORTER 4; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45A; HLA DPB1 ANTIGEN; HLA DR ANTIGEN; INSULIN RECEPTOR SUBSTRATE 2; MAMMALIAN TARGET OF RAPAMYCIN; NDUFA10 PROTEIN; NDUFA5 PROTEIN; NDUFB10 PROTEIN; NDUFB4 PROTEIN; NDUFB5 PROTEIN; NDUFS1 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN P53; PROTEIN TNFRSF10B; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RNA; SUCCINATE DEHYDROGENASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; MUSCLE PROTEIN; TRANSCRIPTOME;

AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; ENERGY METABOLISM; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFECTION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION; IMMUNOLOGY;

APOPTOSIS; DIABETES MELLITUS, TYPE 2; HUMANS; INFECTION; INSULIN RESISTANCE; MUSCLE PROTEINS; MUSCLE, SKELETAL; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 85006642305     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.11.055     Document Type: Article

References (24)

1. [1] Kahn, S.E., Cooper, M.E., Del Prato, S., Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383 (2014), 1068–1083.
2. [2] DeFronzo, R.A., Tripathy, D., Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32:Suppl 2 (2009), S157–S163.
3. [3] Fradkin, J.E., Hanlon, M.C., Rodgers, G.P., NIH precision medicine initiative: implications for diabetes research. Diabetes Care 39 (2016), 1080–1084.
4. [4] Jin, W., Goldfine, A.B., Boes, T., Henry, R.R., Ciaraldi, T.P., Kim, E.Y., Emecan, M., Fitzpatrick, C., Sen, A., Shah, A., Mun, E., Vokes, V., Schroeder, J., Tatro, E., Jimenez-Chillaron, J., Patti, M.E., Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J. Clin. Invest. 121 (2011), 918–929.
5. [5] Patti, M.E., Butte, A.J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., Kohane, I., Costello, M., Saccone, R., Landaker, E.J., Goldfine, A.B., Mun, E., DeFronzo, R., Finlayson, J., Kahn, C.R., Mandarino, L.J., Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 8466–8471.
6. [6] Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstrale, M., Laurila, E., Houstis, N., Daly, M.J., Patterson, N., Mesirov, J.P., Golub, T.R., Tamayo, P., Spiegelman, B., Lander, E.S., Hirschhorn, J.N., Altshuler, D., Groop, L.C., PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34 (2003), 267–273.
7. [7] Sreekumar, R., Halvatsiotis, P., Schimke, J.C., Nair, K.S., Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 51 (2002), 1913–1920.
8. [8] Scott, L.J., Erdos, M.R., Huyghe, J.R., Welch, R.P., Beck, A.T., Wolford, B.N., Chines, P.S., Didion, J.P., Narisu, N., Stringham, H.M., Taylor, D.L., Jackson, A.U., Vadlamudi, S., Bonnycastle, L.L., Kinnunen, L., Saramies, J., Sundvall, J., Albanus, R.D., Kiseleva, A., Hensley, J., Crawford, G.E., Jiang, H., Wen, X., Watanabe, R.M., Lakka, T.A., Mohlke, K.L., Laakso, M., Tuomilehto, J., Koistinen, H.A., Boehnke, M., Collins, F.S., Parker, S.C., The genetic regulatory signature of type 2 diabetes in human skeletal muscle. Nat. Commun., 7, 2016, 11764.
9. [9] Mele, M., Ferreira, P.G., Reverter, F., DeLuca, D.S., Monlong, J., Sammeth, M., Young, T.R., Goldmann, J.M., Pervouchine, D.D., Sullivan, T.J., Johnson, R., Segre, A.V., Djebali, S., Niarchou, A., Consortium, G.T., Wright, F.A., Lappalainen, T., Calvo, M., Getz, G., Dermitzakis, E.T., Ardlie, K.G., Guigo, R., Human genomics. The human transcriptome across tissues and individuals. Science 348 (2015), 660–665.
10. [10] Keen, J.C., Moore, H.M., The genotype-tissue expression (GTEx) project: linking clinical data with molecular analysis to advance personalized medicine. J. Pers. Med. 5 (2015), 22–29.
11. [11] Love, M.I., Huber, W., Anders, S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 2014, 550.
12. [12] Leek, J.T., Svaseq: Removing batch effects and other unwanted noise from sequencing data. Nucleic Acids Res., 42, 2014.
13. [13] Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 2015, e47.
14. [14] Yu, G., Wang, L.G., Han, Y., He, Q.Y., clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16 (2012), 284–287.
15. [15] Luo, W., Brouwer, C., Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics 29 (2013), 1830–1831.
16. [16] Rosenbaum, P.R., Optimal matching for observational studies. J. Am. Stat. Assoc. 84 (1989), 1024–1032.
17. [17] Phielix, E., Mensink, M., Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol. Behav. 94 (2008), 252–258.
18. [18] Fiordaliso, F., Leri, A., Cesselli, D., Limana, F., Safai, B., Nadal-Ginard, B., Anversa, P., Kajstura, J., Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 50 (2001), 2363–2375.
19. [19] Shoelson, S.E., Lee, J., Goldfine, A.B., Inflammation and insulin resistance. J. Clin. Invest. 116 (2006), 1793–1801.
20. [20] Tornatore, L., Thotakura, A.K., Bennett, J., Moretti, M., Franzoso, G., The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol. 22 (2012), 557–566.
21. [21] Shah, B.R., Hux, J.E., Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26 (2003), 510–513.
22. [22] Casqueiro, J., Casqueiro, J., Alves, C., Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J. Endocrinol. Metab. 16:Suppl 1 (2012), S27–S36.
23. [23] Engstrom, G., Hedblad, B., Eriksson, K.F., Janzon, L., Lindgarde, F., Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54 (2005), 570–575.
24. [24] Pociot, F., McDermott, M.F., Genetics of type 1 diabetes mellitus. Genes Immun. 3 (2002), 235–249.